SPPI Profile
Spectrum Pharmaceuticals, Inc., headquartered in Boston, Massachusetts, is a prominent biopharmaceutical company focused on advancing oncology and hematology drug products. Founded in 1987 as NeoTherapeutics, Inc., the company rebranded to Spectrum Pharmaceuticals, Inc. in December 2002, reflecting its commitment to developing innovative therapies to address unmet medical needs in cancer treatment.
At the forefront of Spectrum Pharmaceuticals' pipeline is Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor designed to mitigate chemotherapy-induced neutropenia. Additionally, the company is advancing Poziotinib, an irreversible tyrosine kinase inhibitor targeting non-small cell lung cancer with various mutations, demonstrating its dedication to precision medicine and therapeutic advancement.
Innovative therapies in Spectrum Pharmaceuticals' portfolio also include Anti-CD20-IFNa, an antibody-interferon fusion molecule currently in Phase I development. This promising candidate aims to address relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma, underscoring the company's commitment to expanding treatment options in oncology.
Spectrum Pharmaceuticals collaborates extensively through co-development, commercialization, and in-licensing agreements with partners like Hanmi Pharmaceutical Co. Ltd., The University of Texas M.D. Anderson Cancer Center, and ImmunGene, Inc. These partnerships bolster its research capabilities and accelerate the translation of scientific discoveries into potential therapies for patients worldwide. As Spectrum Pharmaceuticals continues to drive innovation in the biopharmaceutical industry, it remains dedicated to improving outcomes and quality of life for individuals facing cancer and hematologic disorders.
|
